Yahoo! Finance: CBST News

Senior Portfolio Manager Picks Cubist Pharmaceuticals (CBST): Strong Product Offerings And Sky High Sales Make This Stock A Top Pick (Wall Street Transcript)

Wed, 23 Dec 2009 20:06:00 Etc/GMT

67 WALL STREET, New York - December 23, 2009 - The Wall Street Transcript has just published its GARP And Other Investing Strategies Report offering a timely review of the sector to serious investors and industry executives. This 59 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

This Week's Biotech Deal-Making and Financing (at Seeking Alpha)

Sun, 20 Dec 2009 12:02:14 Etc/GMT

Forma Therapeutics closes $28.5M round (at bizjournals.com)

Thu, 17 Dec 2009 20:05:20 Etc/GMT

CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St (EDGAR Online)

Thu, 17 Dec 2009 17:04:19 Etc/GMT

Cubist completes $92.5 million Calixa buyout (AP)

Wed, 16 Dec 2009 22:36:32 Etc/GMT

Cubist Pharmaceuticals Inc. said Wednesday it completed the $92.5 million cash buyout of biopharmaceutical company Calixa Therapeutics Inc.

Cubist Pharmaceuticals Completes Acquisition Of Calixa Therapeutics (Business Wire)

Wed, 16 Dec 2009 21:07:00 Etc/GMT

LEXINGTON, Mass.----Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company has completed its previously announced acquisition of Calixa Therapeutics Inc., a biopharmaceutical company focused on the development of novel antibiotics that address the expanding problem of multi-drug resistant Gram-negative pathogens.

Cubist's acquisition to add value (Zacks.com)

Wed, 16 Dec 2009 16:45:44 Etc/GMT

Cubist Pharmaceuticals decided to acquire a privately held biopharmaceutical company Calixa Therapeutics for an upfront payment of $92.5 million

CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E (EDGAR Online)

Mon, 14 Dec 2009 19:25:39 Etc/GMT

Biotech Stocks: Sunesis, Generex, Cubist lead drug stocks higher (at MarketWatch)

Mon, 14 Dec 2009 18:29:00 Etc/GMT

Sunesis Pharmaceuticals help pace drug stocks' gains, as the drug developer continues its upward trek after soaring last week on positive news about its new leukemia drug.

Cubist to pay up to $310M for Calixa (at bizjournals.com)

Mon, 14 Dec 2009 15:05:14 Etc/GMT

Cubist Pharmaceuticals pays $92.5M for Calixa (AP)

Mon, 14 Dec 2009 12:59:36 Etc/GMT

Cubist Pharmaceuticals Inc. said Monday it will pay $92.5 million in cash to buy biopharmaceutical company Calixa Therapeutics Inc. in a deal it expects to close this month.

How to Play Generic Drug Stocks (at Minyanville.com)

Mon, 14 Dec 2009 12:40:00 Etc/GMT

As the patent cliff nears, copycats are gearing up.

Cubist Pharmaceuticals to Acquire Calixa Therapeutics (Business Wire)

Mon, 14 Dec 2009 05:01:00 Etc/GMT

LEXINGTON, Mass.----Cubist Pharmaceuticals, Inc. a leading acute care therapeutics company, announced today the signing of a definitive agreement under which Cubist has agreed to acquire privately held Calixa Therapeutics Inc., a biopharmaceutical company focused on the development of novel antibiotics that address the expanding problem of multi-drug resistant Gram-negative pathogens.

Trial date set for Cubist suit against Teva (at bizjournals.com)

Fri, 11 Dec 2009 19:05:23 Etc/GMT

Trial Date Set for CUBICIN® Patent Litigation (Business Wire)

Fri, 11 Dec 2009 17:05:00 Etc/GMT

LEXINGTON, Mass.----Cubist Pharmaceuticals, Inc. today announced that a trial date has been set for patent litigation in the U.S. District Court for the District of Delaware against Teva Parenteral Medicines, Inc. , Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. alleging infringement of Cubist’s US Patent Nos. 6,468,967 and 6,852,689, which expire on September 24, 2019, and US Patent No.

Cubist halts trial enrollment over death-rate concerns (at bizjournals.com)

Mon, 7 Dec 2009 17:05:29 Etc/GMT

CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (EDGAR Online)

Mon, 7 Dec 2009 16:03:23 Etc/GMT

Cubist stops enrollment in anti-bleeding studies (AP)

Thu, 3 Dec 2009 20:26:05 Etc/GMT

Cubist Pharmaceuticals Inc. said Thursday it stopped enrolling patients in trials of a drug intended to reduce bleeding during heart surgery because of deaths among patients that took it.

Cubist Pharma rises after upgrade to 'Outperform' (AP)

Thu, 3 Dec 2009 18:42:06 Etc/GMT

Shares of Cubist Pharmaceuticals Inc. rose Thursday after an analyst upgraded the stock, saying he believes Cubist will successfully defend the patents on its antibiotic Cubicin, and expects sales will remain strong.

Cubist halts clinical trial enrollment (at MarketWatch)

Thu, 3 Dec 2009 14:36:30 Etc/GMT